Background
==========

Esophageal cancer is the sixth most common cause of cancer-related deaths worldwide \[[@b1-medscimonit-23-4619]\]. Approximately, 70% of global esophageal cancer cases occur in China, where it is the fourth cause of cancer death \[[@b2-medscimonit-23-4619]\]. Esophageal squamous cell carcinoma (ESCC) accounts for more than 90% of esophageal cancer cases in Chinese patients \[[@b3-medscimonit-23-4619]\]. Despite recent improvements in therapy, the outcome of ESCC remains dismal \[[@b4-medscimonit-23-4619],[@b5-medscimonit-23-4619]\].

Recent advances in cancer immunological therapeutics have revealed the importance of signaling between programmed death-1 (PD-1), mainly expressed on antigen-experienced T cells, and its ligand PD-L1, expressed on tumor cells and antigen presenting cells \[[@b6-medscimonit-23-4619]\]. The combination of PD-1 and PD-L1 is the key immune checkpoint receptor to inhibit T-cell activation \[[@b6-medscimonit-23-4619]\], inducing impaired immune response and worse prognosis in various cancers \[[@b7-medscimonit-23-4619],[@b8-medscimonit-23-4619]\]. Clinical trials have demonstrated that patients with malignant melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma benefit from anti-PD-1 and anti-PD-L1 therapy \[[@b9-medscimonit-23-4619]--[@b11-medscimonit-23-4619]\]. However, recent literature reported that patients with high expression of PD-1 and PD-L1 had better prognosis in breast cancer, metastatic melanoma, colorectal cancer, pulmonary squamous cell carcinoma, and ovarian cancer \[[@b12-medscimonit-23-4619]--[@b16-medscimonit-23-4619]\]. Moreover, only a fraction of patients respond to PD-1 or PD-L1 blockage \[[@b17-medscimonit-23-4619],[@b18-medscimonit-23-4619]\]. Therefore, the role of PD-L1 as a predictive biomarker for immune treatment response in various solid tumors remains controversial \[[@b8-medscimonit-23-4619],[@b19-medscimonit-23-4619],[@b20-medscimonit-23-4619]\].

We previously identified PD-L1 expression of 41.4% (222/536) in our ESCC cohort \[[@b21-medscimonit-23-4619]\], and found that PD-L1 expression differed significantly by tumor location, grade, lymph node metastases, and disease stage \[[@b21-medscimonit-23-4619]\]. Moreover, patients with positive PD-L1 expression had reduced risk for disease relapse compared to those without PD-L1 expression \[[@b21-medscimonit-23-4619]\]. Our finding of an inverse association between the expression of this favorable predictor PD-L1 and lymph node metastasis prompted us to speculate that PD-L1 might be induced by an active immune response including T-cell proliferation.

High numbers of tumor-infiltrating lymphocytes (TILs) have been repeatedly shown to provide a significant survival advantage in ESCC. Particularly the presence of T cells (CD3+) and various T cell subpopulations (e.g., CD4+, CD8+, CD103+) have been shown to be indicators of a better prognosis \[[@b22-medscimonit-23-4619],[@b23-medscimonit-23-4619]\]. Considering that PD-L1 expression could be induced by activated T cells \[[@b24-medscimonit-23-4619],[@b25-medscimonit-23-4619]\], we next explored the potential association between PD-L1 expression and TIL abundance in ESCC.

In the present study, we systematically investigated the clinical significance of tumor-infiltrating (intraepithelial and stromal) lymphocytes in patients using 536 ESCC tissue samples. The survival impacts of various immunological factors were also assessed.

Material and Methods
====================

Study population
----------------

Five hundred and thirty-six patients who underwent radical surgery for ESCC between January 2008 and April 2012 in Department of Thoracic Surgery at Zhejiang Cancer Hospital were included in the study. No patients received neoadjuvant treatment or immunotherapy. The demographic and clinical data of patients including age, gender, tumor site, histological grade, lymph node status, pTNM stage, smoking experience, alcohol drinking, and family history were abstracted from clinical records. The extent of the disease was determined by pTNM staging based on the 7th IUCC/AJCC recommendations. All tissue specimens used in our study were obtained from the tissue bank of Zhejiang Cancer Hospital and all patients provided informed consent before surgery. The protocol of the study was approved by the Institutional Review Board of Zhejiang Cancer Hospital.

Follow-up visits were performed every three months for the first two years after surgery, and every six months in the third year and yearly thereafter. At each visit, a clinical history was taken and a physical examination was performed. Routine diagnostic imaging methods included gastroscopy and computer tomography (CT). The median follow-up time was 32.7 months with a range from 1.0 to 88.7 months. The overall survival (OS) data were available for 451 patients (84.1%); among whom 261 patients (57.9%) died during follow-up. Disease free survival (DFS) data were available for 403 patients (75.2%), and 224 patients (41.8%) underwent disease relapse, of which 190 patients (84.8%) died.

Tissue microarray
-----------------

Formalin-fixed paraffin-embedded (FFPE) surgical specimens were hematoxylin and eosin (H&E) stained, and ESCC was confirmed by two senior pathologists independently. The paraffin tissue blocks of 536 cases of esophageal cancer were used in the construction of the tissue microarray. In brief, the H&E-stained standard slides were reviewed from each section of esophageal cancer tissue, and one representative tumor area of each tumor (2 mm diameter) was removed from the FFPE tissue blocks. Tissue microarray was sectioned at 3 μm and mounted on glass slides for the immunohistochemistry analysis.

Immunohistochemistry analysis
-----------------------------

Standard immunohistochemical analysis was performed against primary antibody directed CD3 (clone SP7, diluted at 1: 100, Abcam, Cambridge, UK), CD4 (clone B468A1, diluted at 1: 200, Santa Cruz, Texas, USA) and CD8 (clone 144B, diluted at 1: 100, Abcam, Cambridge, UK). Antigen retrieval was achieved using EDTA buffer (pH 9.0) in a pressure cooker for 20 minutes. After neutralization of endogenous peroxidase, tissue microarray slides were pre-incubated with blocking serum and then were incubated with primary antibody for 45 minutes at room temperature. After three five-minute washes with PBS, the slides were treated with the horseradish peroxidase (HRP)-labeled secondary antibody (Dako, Glostrup, Denmark) for 20 minutes at room temperature, then washed in PBS. Finally, the reaction products were visualized with 3,3′-diaminobenzidine (DAB, Dako, Glostrup, Denmark) and the slides were counterstained with hematoxylin. After being dehydrated, slides were mounted in resin.

Evaluation of immunohistochemistry
----------------------------------

The tumor sections were screened at low power magnification (100×), and high power fields (400×) were selected to evaluated the immunoreactivity. All immunostained slides were examined independently by two senior pathologists in a blind manner. The average of the values obtained by the two observers was recorded and used in the statistical analysis. In accordance with previously published approaches \[[@b26-medscimonit-23-4619]\], intraepithelial TILs (iTILs) were defined as lymphocytes located within tumor cell nests or in direct contact with the ESCC epithelial cells, whereas stromal TILs (sTILs) were defined as lymphocytes in the adjacent peritumoral stroma without direct contact with the carcinoma cells. Areas of necrosis and artifacts, and cells within the vessels were omitted. All samples were scored according to the frequency of positive cells in all nucleated cells (as percentage) on the stained TMA core. The median leukocyte count was used as cutoff to categorize each case into either a high or low group. The tissues having no TILs were excluded from our study; hence data of 514 patients were used to assess the CD3 expression, 530 cases were used to evaluate the CD4 expression, and 527 cases were used for CD8 analysis.

Statistical analysis
--------------------

Differences between groups were compared using the chi-square test or the Mann-Whitney U test for variables. Spearman's coefficient rank test was used to evaluate the correlation between tumor-infiltrating T lymphocyte, and PD-L1 expression. Associations with DFS and OS were analyzed using the Kaplan-Meier method, log-rank test and the Cox proportional hazards model. All the statistical analyses were performed with SPSS 13.0 for Windows (Chicago, IL, USA), and *p* value ≤0.05 in a two-tailed test was considered statistically significant.

Results
=======

Expression of TIL
-----------------

The infiltrating T lymphocytes were categorized by location in the tumor intraepithelium (i) or stroma (s), and the representative images of CD3+, CD4+, CD8+ lymphocyte infiltration are shown in [Figure 1](#f1-medscimonit-23-4619){ref-type="fig"}. The expressions of CD3, CD4, and CD8 were found to be located on both the membrane and in the cytoplasm of TILs. A total of 536 patients were enrolled in this study. Among them, 40.9% (210 patients) had intraepithelial CD3 (iCD3) expression, and 39.1% (199 patients) had stromal CD3 (sCD3) expression, but no significant difference between the infiltration of iCD3+ and sCD3+ lymphocytes was found (*p*\>0.05). Regarding CD8 expression in the 527 patients, 16.7% (88 patients) were intraepithelial expression, and 15.4% (81 patients) were stromal expression. Also, the accumulation of iCD8+ lymphocytes was not related to the sCD8+ lymphocytes (*p*\>0.05). Importantly, the infiltration of iCD4+ lymphocytes was 44.2% (234/530), which was significantly higher than that in stromal regions (28.9%, 153/530, *p*\<0.001).

Clinicopathological associations with TIL expression
----------------------------------------------------

The demographics of 536 patients are summarized in [Table 1](#t1-medscimonit-23-4619){ref-type="table"}. The median age of the patients at diagnosis was 60 (range 37--77) years. Among these patients, 73.5% (394/536) were younger than 65 years, 86.0% (464/536) were male, 25.7% (138/536) had family history, 71.3% (382/536) were alcohol drinkers, and 75.2% (403/536) were smokers. Within the cohort, 35 patients (6.5%) had well differentiated tumors, 377 (70.3%) moderately differentiated tumors, and 124 (23.1%) poorly differentiated tumors. In accordance with the 7th IUCC/AJCC staging system, 61 (11.4%) patients were stage I, 195 (36.4%) patients were stage II, 273 (50.9%) patients were stage III, and seven (1.3%) patients were stage IV. In the present study, we analyzed the correlations between the clinicopathological features and the infiltration of CD3+, CD4+, and CD8+ lymphocytes in ESCC tissues. As shown in [Table 1](#t1-medscimonit-23-4619){ref-type="table"}[](#t2-medscimonit-23-4619){ref-type="table"}[](#t3-medscimonit-23-4619){ref-type="table"}[](#t4-medscimonit-23-4619){ref-type="table"}[](#t5-medscimonit-23-4619){ref-type="table"}--[6](#t6-medscimonit-23-4619){ref-type="table"}, increased iCD3+, sCD4+, and iCD8+ lymphocytes were significantly associated with advanced tumor differentiation (*p*\<0.05). Furthermore, high infiltrations of sCD4+ and sCD8+ lymphocytes were more frequently observed in patients with alcohol drinking and smoking experience (*p*\<0.05). However, sCD3+ and iCD4+ lymphocytes had no significant correlation with any of the clinicopathological parameters (*p*\>0.05).

Correlations between PD-L1 and TIL expression
---------------------------------------------

Based on the fact that PD-L1 expression had close interactions with TILs in the tumor microenvironment \[[@b20-medscimonit-23-4619]\], combining our previous study of an inverse association between PD-L1 expression and lymph node metastasis \[[@b21-medscimonit-23-4619]\], we hypothesized that PD-L1 expression could be induced by increased T-cell infiltration. Then the relevance of PD-L1 expression and various TIL markers was investigated. Unexpectedly, results showed an inverse trend of PD-L1 expression and lymphocytes infiltration, especially in sCD3+ lymphocytes ([Table 7](#t7-medscimonit-23-4619){ref-type="table"}, *p*=0.027). Correlation analysis revealed the similar results (r=−0.098, *p*=0.027). Though infiltrated T cells have been reported to induce better outcome in ESCC \[[@b23-medscimonit-23-4619]\], the patients in our study with PD-L1 expression were more likely to have less T cells infiltration.

Prognostic impacts of the immune microenvironment
-------------------------------------------------

To identify variables of potential prognostic significance in the patients with ESCC, the impacts of TILs subgroup and other clinicopathological parameters on the prognosis were explored. [Table 7](#t7-medscimonit-23-4619){ref-type="table"} shows that increased iCD4+ lymphocytes were significantly associated with prolonged overall survival (OS) in ESCC (*p*=0.007), and the Kaplan-Meier figures are shown in [Figure 2](#f2-medscimonit-23-4619){ref-type="fig"}. In addition, multivariate analysis implicated that iCD4+ lymphocytes infiltration was an independent predictor for OS after adjusting by clinicopathological factors in ESCC (hazard ratio \[HR\]=0.67, 95% confidence interval \[CI\]: 0.51--0.88, *p*=0.04, [Table 8](#t8-medscimonit-23-4619){ref-type="table"}). However, no prognostic significance was found for sCD4+, iCD3+, sCD3+, iCD8+, or sCD8+ lymphocytes in ESCC (*p*\>0.05).

Discussion
==========

In our previous study, we identified that PD-L1 could be a favorable indicator of prognosis in ESCC and patients with its expression were more likely to have less lymph node metastasis \[[@b21-medscimonit-23-4619]\]. We thus hypothesized the positive prognostic effect of PD-L1 might be induced by increased T-cell infiltration. However, in this study, we detected an inverse association between immune T-cell abundance and PD-L1 expression in ESCC, indicating the interaction of PD-L1 and PD-1 might inhibit the functions of TILs.

Our findings in this study are in accordance with earlier reports about a significantly inverse correlation between PD-L1 expression and infiltrated T lymphocytes \[[@b27-medscimonit-23-4619]--[@b29-medscimonit-23-4619]\]. In addition, a study of NSCLC elucidated that the PD-L1 protein expression pattern was related to changeable T-cell density within the tumor microenvironment \[[@b30-medscimonit-23-4619]\]. Therefore, the favorable prognostic effect of PD-L1 might be based on regulatory of the complicated immune network, like the activation of different immune cell subpopulations, like γδ T cells \[[@b31-medscimonit-23-4619]\], and the secretion of certain cytokines such as IL-10 and interferon γ \[[@b32-medscimonit-23-4619]--[@b34-medscimonit-23-4619]\]. Meanwhile, the prognostic significance of PD-L1 has been proven to be relevant to the mutational burden \[[@b35-medscimonit-23-4619]\], inducing increased presentation of neo-antigens by tumor cells \[[@b17-medscimonit-23-4619]\]. However, other studies about the presence of TILs in human tumor systems including ESCC have showed a positive or no association with PD-L1 expression \[[@b33-medscimonit-23-4619],[@b36-medscimonit-23-4619]--[@b38-medscimonit-23-4619]\]. Taken together, the regulatory effect of the complicated immune network in the tumor microenvironment has not been fully determined until now.

In the present study, we also explored the impact of tumor-infiltrating lymphocytes on the clinical significance in ESCC. The cooperation of CD4+ and CD8+ T cells has been well-documented in host immune responses against various tumors including ESCC \[[@b22-medscimonit-23-4619],[@b23-medscimonit-23-4619]\]. In our study, the total number of CD4+ TILs in intraepithelium was markedly higher than those in stromal areas. Consistent with our study, Hatogai et al. also found intraepithelial TILs had significantly increased levels compared to stromal compartments, conferring more clinical prognostic value in ESCC \[[@b38-medscimonit-23-4619]\].

In line with previous reports in ovarian carcinoma \[[@b39-medscimonit-23-4619]\], we observed that patients with increased infiltration of iCD4+ lymphocytes had longer OS compared to those with decreased infiltration, while sCD4+ lymphocytes was not correlated with the outcomes in ESCC. The localization of TILs seems have major relevance with regards to their prognostic impact; this finding should encourage highly interesting research in the future. Furthermore, subpopulations of CD4+ T cells could have different functional impacts on the immune environment; for instance CD4+ T cells can have anti-tumorigenic effects when the Th1 subset is active in secreting pro-inflammatory cytokines, whereas a pro-tumorigenic effect can be predominant when Th2 cells secrete anti-inflammatory cytokines \[[@b40-medscimonit-23-4619]\]. However, in our study, no correlations between the infiltration of iCD3+ lymphocytes and sCD3+ lymphocytes and their impacts on the prognosis were found. And iCD8+ and sCD8+ lymphocytes infiltration was also not associated with clinical outcome in ESCC. Notably, one study found increased CD8+ TILs infiltration were independent favorable prognostic factors in esophageal adenocarcinoma \[[@b41-medscimonit-23-4619]\], while another study indicated that the TILs were not the prognostic markers for long-term survival in patients with esophageal adenocarcinoma \[[@b42-medscimonit-23-4619]\]. These controversial results were likely caused by factors in the tissue microenvironment which may alter T-cell phenotype and function early during esophageal disease progression and may represent targets for immune intervention \[[@b43-medscimonit-23-4619]\]. Further investigations regarding the impact on clinical outcomes of the balance of immune infiltrating cells are needed.

Additionally, the presence of stromal TILs infiltration more than intraepithelial infiltration was correlated with alcohol drinking and smoking experience. As previously described, smoking history of a patient was associated with a greater risk of cancer development than patients without those characteristics, and were characterized by abundant and deregulated inflammation \[[@b44-medscimonit-23-4619]\], suggesting a linkage between inflammatory processes affecting the smokers or alcohol drinkers and immune response status of tumors \[[@b30-medscimonit-23-4619]\]. The selective recruitment of T cells to the stromal compartment of these esophageal cancers suggests that these stromal TILs are less affected by tumor-derived inhibitory factors than in the intraepithelial regions, which are located in direct contact with malignant cells \[[@b30-medscimonit-23-4619]\]. Unlike an earlier study \[[@b22-medscimonit-23-4619]\], we observed patients with increased TILs were more likely to harbor poor tumor differentiation; meanwhile, some other authors reported no association of TILs accumulation with tumor grade of ESCC \[[@b23-medscimonit-23-4619],[@b38-medscimonit-23-4619]\]. Potential explanations for this finding might be induced from a misbalance of the effect of tumor-derived factors and immune responses.

Based on a large cohort of operable ESCC patients, our study systematically described the immune status in the tumor microenvironment. To our knowledge, this is the first study that has indicated that increased iCD4+ lymphocytes infiltration was an independent favorable predictor for prognosis in ESCC. In addition, this study has its own limitations. Our data did not include the responses rate of anti-PD-1 and anti-PD-L1 therapeutics in ESCC patients; and functional studies to validate and understand the roles of TILs and cytokines such as interferon γ are urgently needed.

Conclusions
===========

The iCD4+ lymphocytes infiltration is an independent favorable factor for prognosis in ESCC. The TILs infiltration in ESCC tissues was inversely associated with the expression of PD-L1. Therefore, the profiles of immune cells may provide additional information for patient outcomes and help to stratify patients who will benefit more from immunotherapy.
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![Immunohistochemical staining for human esophageal squamous cell carcinoma (ESCC) tissues recognizing the expressions of CD3 (**top**), CD4 (**middle**) and CD8 (**bottom**) in tumor-infiltrating lymphocytes. Representative cases of: intraepithelial (i) CD3-negative (**A**), iCD3-positive (**B**), stromal (s) CD3-negative (**C**), sCD3-positive (**D**), iCD4-negative (**E**), iCD4-positive (**F**), sCD4-negative (**G**), sCD4-positive (**H**), iCD8-negative (**I**), iCD8-positive (**J**), sCD8-negative (**K**), and sCD8-positive (**L**). Original magnification 200×.](medscimonit-23-4619-g001){#f1-medscimonit-23-4619}

![Kaplan-Meier curves of disease-free survival (DFS) and overall survival (OS) in esophageal squamous cell carcinoma (ESCC) based on tumor-infiltrating lymphocytes. (**A--D**), increased iCD3+ or sCD3+ lymphocytes infiltration was not associated with DFS and OS in ESCC (*p*\>0.05); (**E--H**), increased iCD4+ lymphocytes were significantly associated with longer OS in ESCC (*p*=0.007); (**I--L**), no prognostic significance was found for iCD8+ or sCD8+ lymphocytes in ESCC (*p*\>0.05).](medscimonit-23-4619-g002){#f2-medscimonit-23-4619}

###### 

Clinicopathological associations with iCD3 expression in ESCC.

  Category          All cases     iCD3          *p* Value     
  ----------------- ------------- ------------- ------------- -------------
  Age                                                         
   \<65             139 (27.0%)   75 (54.0%)    64 (46.0%)    0.145
   ≥65              375 (73.0%)   229 (61.1%)   146 (38.9%)   
  Gender                                                      
   Male             444 (86.4%)   265 (59.7%)   179 (40.3%)   0.530
   Female           70 (13.6%)    39 (55.7%)    31 (44.3%)    
  Tumor site                                                  
   Upper            15 (2.9%)     8 (53.3%)     7 (46.7%)     0.784
   Middle           146 (28.4%)   84 (57.5%)    62 (42.5%)    
   Lower            353 (68.7%)   212 (60.1%)   141 (39.9%)   
  Tumor grade                                                 
   Well             32 (6.2%)     23 (71.9%)    9 (28.1%)     ***0.020***
   Moderate         362 (70.4%)   222 (61.3%)   140 (38.7%)   
   Poor             120 (23.3%)   59 (49.2%)    61 (50.8%)    
  Tumor stage                                                 
   I                58 (11.3%)    33 (56.9%)    25 (43.1%)    0.544
   II               188 (36.6%)   115 (61.2%)   73 (38.8%)    
   III              262 (51.0%)   151 (57.6%)   111 (42.4%)   
   IV               6 (1.2%)      5 (83.3%)     1 (16.7%)     
  Family history                                              
   Yes              132 (25.7%)   73 (55.3%)    59 (44.7%)    0.298
   No               382 (74.3%)   231 (60.5%)   151 (39.5%)   
  Alcohol history                                             
   Yes              363 (70.6%)   208 (57.3%)   155 (42.7%)   0.187
   No               151 (29.4%)   96 (63.6%)    55 (36.4%)    
  Smoking history                                             
   Yes              386 (75.1%)   234 (60.6%)   152 (39.4%)   0.237
   No               128 (24.9%)   70 (54.7%)    58 (45.3%)    
  BMI                                                         
   \<18             70 (13.6%)    38 (54.3%)    32 (45.7%)    0.274
   18--25           395 (76.8%)   241 (61.0%)   154 (39.0%)   
   \>25             49 (9.5%)     25 (51.0%)    24 (49.0%)    
  Total             514           304 (59.1%)   210 (40.9%)   

Bold-italic value was statistically significant (*p*≤0.05).

###### 

Clinicopathological associations with sCD3 expression in ESCC.

  Category          All cases     sCD3          *p* Value     
  ----------------- ------------- ------------- ------------- -------
  Age                                                         
   \<65             139 (27.3%)   82 (59.0%)    57 (41.0%)    0.588
   ≥65              370 (72.7%)   228 (61.6%)   142 (38.4%)   
  Gender                                                      
   Male             439 (86.2%)   268 (61.0%)   171 (39.0%)   0.867
   Female           70 (13.8%)    42 (60.0%)    28 (40.0%)    
  Tumor site                                                  
   Upper            15 (2.9%)     7 (46.7%)     8 (53.3%)     0.276
   Middle           146 (28.7%)   84 (57.5%)    62 (42.5%)    
   Lower            348 (68.4%)   219 (62.9%)   129 (37.1%)   
  Tumor grade                                                 
   Well             31 (6.1%)     19 (61.3%)    12 (38.7%)    0.653
   Moderate         361 (70.9%)   224 (62.0%)   137 (38.0%)   
   Poor             117 (23.0%)   67 (57.3%)    50 (42.7%)    
  Tumor stage                                                 
   I                58 (11.4%)    35 (60.3%)    23 (39.7%)    0.212
   II               187 (36.7%)   117 (62.6%)   70 (37.4%)    
   III              258 (50.7%)   152 (58.9%)   106 (41.1%)   
   IV               6 (1.2%)      6 (100.0%)    0 (0.0%)      
  Family history                                              
   Yes              129 (25.3%)   70 (54.3%)    59 (45.7%)    0.074
   No               380 (74.7%)   240 (63.2%)   140 (36.8%)   
  Alcohol history                                             
   Yes              358 (70.3%)   218 (60.9%)   140 (39.1%)   0.247
   No               151 (29.7%)   92 (60.9%)    55 (39.1%)    
  Smoking history                                             
   Yes              381 (74.9%)   233 (61.2%)   148 (38.8%)   0.841
   No               128 (25.1%)   77 (60.2%)    51 (39.8%)    
  BMI                                                         
   \<18             70 (13.8%)    40 (57.1%)    30 (42.9%)    0.176
   18--25           391 (76.8%)   246 (62.9%)   145 (37.1)    
   \>25             48 (9.4%)     24 (50.0%)    24 (50.0%)    
  Total             509           310 (60.9%)   199 (39.1%)   

###### 

Clinicopathological associations with iCD4 expression in ESCC.

  Category          All cases     iCD4          *p* Value     
  ----------------- ------------- ------------- ------------- -------
  Age                                                         
   \<65             141 (26.6%)   73 (51.8%)    68 (48.2%)    0.255
   ≥65              389 (73.4%)   223 (57.3%)   166 (42.7%)   
  Gender                                                      
   Male             459 (86.6%)   260 (56.6%)   199 (43.4%)   0.348
   Female           71 (13.4%)    36 (50.7%)    35 (49.3%)    
  Tumor site                                                  
   Upper            16 (3.0%)     7 (43.8%)     9 (56.3%)     0.586
   Middle           152 (28.7%)   87 (57.2%)    65 (42.8%)    
   Lower            362 (68.3%)   202 (55.8%)   160 (44.2%)   
  Tumor grade                                                 
   Well             35 (6.6%)     18 (51.4%)    17 (48.6%)    0.784
   Moderate         372 (70.2%)   211 (56.7%)   161 (43.3%)   
   Poor             123 (23.2%)   67 (54.5%)    56 (45.5%)    
  Tumor stage                                                 
   I                59 (11.1%)    31 (52.5%)    28 (47.5%)    0.264
   II               193 (36.4%)   102 (52.8%)   91 (47.2%)    
   III              271 (51.1%)   157 (57.9%)   114 (42.1%)   
   IV               7 (1.3%)      6 (85.7%)     1 (14.3%)     
  Family history                                              
   Yes              134 (25.3%)   76 (56.7%)    58 (43.3%)    0.815
   No               396 (74.7%)   220 (55.6%)   176 (44.4%)   
  Alcohol history                                             
   Yes              377 (71.1%)   212 (56.2%)   165 (43.8%)   0.780
   No               153 (28.9%)   84 (54.9%)    69 (45.1%)    
  Smoking history                                             
   Yes              399 (75.3%)   225 (56.4%)   174 (43.6%)   0.661
   No               131 (24.7%)   71 (54.2%)    60 (45.8%)    
  BMI                                                         
   \<18             71 (13.4%)    37 (52.1%)    34 (47.9%)    0.733
   18--25           407 (76.8%)   231 (56.8%)   176 (43.2%)   
   \>25             52 (9.8%)     28 (53.8%)    24 (46.2%)    
  Total             530           296 (55.8%)   234 (44.2%)   

###### 

Clinicopathological associations with sCD4 expression in ESCC.

  Category          All cases     sCD4          *p* Value     
  ----------------- ------------- ------------- ------------- -------------
  Age                                                         
   \<65             141 (26.6%)   96 (68.1%)    45 (31.9%)    0.351
   ≥65              389 (73.4%)   281 (72.2%)   108 (27.8%)   
  Gender                                                      
   Male             459 (86.6%)   323 (70.4%)   136 (29.6%)   0.325
   Female           71 (13.4%)    54 (76.1%)    17 (23.9%)    
  Tumor site                                                  
   Upper            16 (3.0%)     13 (81.3%)    3 (18.7%)     0.264
   Middle           152 (28.7%)   114 (75.0%)   38 (25.0%)    
   Lower            362 (68.3%)   250 (69.1%)   112 (30.9%)   
  Tumor grade                                                 
   Well             35 (6.6%)     27 (77.1%)    8 (22.9%)     ***0.017***
   Moderate         372 (70.2%)   275 (73.9%)   97 (26.1%)    
   Poor             123 (23.2%)   75 (61.0%)    48 (39.0%)    
  Tumor stage                                                 
   I                59 (11.1%)    40 (67.8%)    19 (32.2%)    0.323
   II               193 (36.4%)   140 (72.5%)   53 (27.5%)    
   III              271 (51.1%)   190 (70.1%)   81 (29.9%)    
   IV               7 (1.3%)      7 (100.0%)    0 (0.0%)      
  Family history                                              
   Yes              134 (25.3%)   95 (70.9%)    39 (29.1%)    0.944
   No               396 (74.7%)   282 (71.2%)   114 (28.8%)   
  Alcohol history                                             
   Yes              377 (71.1%)   257 (68.2%)   120 (31.8%)   ***0.018***
   No               153 (28.9%)   120 (78.4%)   33 (21.6%)    
  Smoking history                                             
   Yes              399 (75.3%)   275 (68.9%)   124 (31.1%)   ***0.050***
   No               131 (24.7%)   102 (77.9%)   29 (22.1%)    
  BMI                                                         
   \<18             71 (13.4%)    48 (67.6%)    23 (32.4%)    0.527
   18--25           407 (76.8%)   289 (71.0%)   118 (29.0%)   
   \>25             52 (9.8%)     40 (76.9%)    12 (423.1%)   
  Total             530           377 (71.1%)   153 (28.9%)   

Bold-italic value was statistically significant (*p*≤0.05).

###### 

Clinicopathological associations with iCD8 expression in ESCC.

  Category          All cases     iCD8          *p* Value    
  ----------------- ------------- ------------- ------------ -------------
  Age                                                        
   \<65             140 (26.6%)   117 (83.6%)   23 (16.4%)   0.920
   ≥65              387 (73.4%)   322 (83.2%)   65 (16.8%)   
  Gender                                                     
   Male             458 (86.9%)   385 (84.1%)   73 (15.9%)   0.228
   Female           69 (13.1%)    54 (78.3%)    15 (21.7%)   
  Tumor site                                                 
   Upper            16 (3.0%)     14 (87.5%)    2 (12.5%)    0.608
   Middle           151 (28.7%)   129 (85.4%)   22 (14.6%)   
   Lower            360 (68.3%)   296 (82.2%)   64 (17.8%)   
  Tumor grade                                                
   Well             34 (6.5%)     34 (100.0%)   0 (0.0%)     ***0.004***
   Moderate         370 (70.2%)   311 (84.1%)   59 (15.9%)   
   Poor             123 (23.3%)   94 (76.4%)    29 (23.6%)   
  Tumor stage                                                
   I                59 (11.2%)    50 (84.7%)    9 (15.3%)    0.958
   II               193 (36.6%)   162 (83.9%)   31 (36.1%)   
   III              268 (50.9%)   221 (82.5%)   47 (17.5%)   
   IV               7 (1.3%)      6 (85.7%)     1 (14.3%)    
  Family history                                             
   Yes              133 (25.2%)   112 (84.2%)   21 (15.8%)   0.745
   No               394 (74.8%)   327 (83.0%)   67 (17.0%)   
  Alcohol history                                            
   Yes              376 (71.3%)   310 (82.4%)   66 (17.6%)   0.406
   No               151 (28.7%)   129 (85.4%)   22 (14.6%)   
  Smoking history                                            
   Yes              397 (75.3%)   332 (83.6%)   65 (16.4%)   0.726
   No               130 (24.7%)   107 (82.3%)   23 (17.7%)   
  BMI                                                        
   \<18             71 (13.5%)    55 (54.3%)    16 (45.7%)   0.365
   18--25           404 (76.7%)   340 (61.0%)   64 (39.0%)   
   \>25             52 (9.9%)     44 (51.0%)    8 (49.0%)    
  Total             527           439 (83.3%)   88 (16.7%)   

Bold-italic value was statistically significant (*p*≤0.05).

###### 

Clinicopathological associations with sCD8 expression in ESCC.

  Category          All cases     sCD8          *p* Value    
  ----------------- ------------- ------------- ------------ -------------
  Age                                                        
   \<65             140 (26.6%)   120 (85.7%)   20 (14.3%)   0.678
   ≥65              387 (73.4%)   326 (84.2%)   61 (15.8%)   
  Gender                                                     
   Male             458 (86.9%)   384 (83.8%)   74 (16.2%)   0.197
   Female           69 (13.1%)    62 (89.9%)    7 (10.1%)    
  Tumor site                                                 
   Upper            16 (3.0%)     13 (81.3%)    3 (18.8%)    0.665
   Middle           151 (28.7%)   131 (86.8%)   20 (13.2%)   
   Lower            360 (68.3%)   302 (83.9%)   58 (16.1%)   
  Tumor grade                                                
   Well             123 (23.3%)   104 (84.6%)   19 (15.4%)   0.832
   Moderate         370 (70.2%)   312 (84.3%)   58 (15.7%)   
   Poor             34 (6.5%)     30 (88.2%)    4 (11.8%)    
  Tumor stage                                                
   I                59 (11.2%)    49 (83.1%)    10 (16.9%)   0.701
   II               193 (36.6%)   164 (85.0%)   29 (15.0%)   
   III              268 (50.9%)   226 (84.3%)   42 (15.7%)   
   IV               7 (1.3%)      7 (1.6%)      0 (0.0%)     
  Family history                                             
   Yes              133 (25.2%)   113 (85.0%)   20 (15.0%)   0.902
   No               394 (74.8%)   333 (84.5%)   61 (15.5%)   
  Alcohol history                                            
   Yes              376 (71.3%)   309 (82.3%)   67 (17.8%)   ***0.014***
   No               151 (28.7%)   137 (90.7%)   14 (9.3%)    
  Smoking history                                            
   Yes              397 (75.3%)   328 (82.6%)   69 (17.4%)   ***0.025***
   No               130 (24.7%)   118 (90.8%)   12 (9.2%)    
  BMI                                                        
   \<18             71 (13.5%)    61 (85.9%)    10 (14.1%)   0.658
   18--25           404 (76.7%)   339 (83.9%)   65 (16.1%)   
   \>25             52 (9.9%)     46 (88.5%)    6 (11.5%)    
  Total             527           446 (84.6%)   81 (15.4%)   

Bold-italic value was statistically significant (*p*≤0.05).

###### 

The associations of T cells infiltration with programmed death-ligand 1 (PD-L1) expression and the survival of esophageal squamous cell carcinoma patients.

  Variables             NO. of patients (%)   PD-L1 expression   *p* Value    HR for DFS    *p* Value        HR for OS   *p* Value        
  --------------------- --------------------- ------------------ ------------ ------------- ---------------- ----------- ---------------- -------------
  **Intraepithelium**                                                                                                                     
  CD3+T cell                                                                                                                              
   Positive             210 (40.9)            81 (38.6)          129 (61.4)   0.143         1.008            0.978       0.954            0.847
   Negative             304 (59.1)            137 (45.1)         167 (54.9)                 (0.596--1.702)               (0.589--1.544)   
  CD4+T cell                                                                                                                              
   Positive             234 (44.2)            98 (41.9)          136 (58.1)   0.940         0.664            0.130       0.517            ***0.007***
   Negative             296 (55.8)            123 (41.6)         173 (58.4)                 (0.392--1.127)               (0.319--0.838)   
  CD8+T cell                                                                                                                              
   Positive             88 (16.7)             29 (33.0)          59 (67.0)    0.079         0.731            0.325       0.943            0.841
   Negative             439 (83.3)            189 (43.1)         250 (56.9)                 (0.391--1.365)               (0.533--1.670)   
  **Stroma**                                                                                                                              
  CD3+T cell                                                                                                                              
   Positive             199 (39.1)            72 (36.2)          127 (63.8)   ***0.027***   0.935            0.771       1.061            0.802
   Negative             310 (60.9)            143 (46.1)         167 (53.9)                 (0.594--1.472)               (0.670--1.680)   
  CD4+T cell                                                                                                                              
   Positive             153 (28.9)            60 (39.2)          93 (60.8)    0.460         0.431            0.418       0.398            0.373
   Negative             377 (71.1)            161 (42.7)         216 (57.3)                 (0.056--3.307)               (0.052--3.029)   
  CD8+T cell                                                                                                                              
   Positive             81 (15.4)             31 (38.3)          50 (61.7)    0.539         0.873            0.597       0.651            0.071
   Negative             446 (84.6)            187 (41.9)         259 (58.1)                 (0.528--1.444)               (0.408--1.037)   

Bold-italic values were statistically significant (*p*≤0.05); HR -- hazard ratio; CI -- confidence interval.

###### 

Prognostic factors for disease free survival and overall survival of operable ESCC patients estimated by multivariate Cox regression analyses.

  Parameters                    DFS                 OS                          
  ----------------------------- ------------------- ------- ------------------- -------------
  Intraepithelial CD3+ T cell                                                   
   Negative                     1.00                        1.00                
   Positive                     1.01 (0.60--1.70)   0.978   1.26 (0.76--2.11)   0.371
  Stromal CD3+ T cell                                                           
   Negative                     1.00                        1.00                
   Positive                     0.94 (0.60--1.47)   0.771   1.17 (0.78--1.75)   0.442
  Intraepithelial CD4+ T cell                                                   
   Negative                     1.00                        1.00                
   Positive                     0.66 (0.40--1.13)   0.130   0.67 (0.51--0.88)   ***0.004***
  Stromal CD4+ T cell                                                           
   Negative                     1.00                        1.00                
   Positive                     0.43 (0.06--3.31)   0.418   0.41 (0.05--3.31)   0.386
  Intraepithelial CD8+ T cell                                                   
   Negative                     1.00                        1.00                
   Positive                     0.73 (0.39--1.37)   0.325   0.89 (0.50--1.58)   0.325
  Stromal CD8+ T cell                                                           
   Negative                     1.00                        1.00                
   Positive                     0.87 (0.53--1.44)   0.597   0.65 (0.40--1.04)   0.075

Bold-italic value was statistically significant (*p*≤0.05); HR -- hazard ratio; CI -- confidence interval; Adjusting for age, sex, tumor site, stage, grade, smoking experience, PD-L1 expression, alcohol drinking and family history.
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